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Abstract
Background: Before the widespread use of primary percutaneous coronary intervention (PCI)
and glycoprotein IIb/IIIa inhibitors (GP IIb/IIIa) left ventricular (LV) thrombus formation had been
reported to complicate up to 20% of acute myocardial infarctions (AMI). The incidence of LV
thrombus formation with these treatment modalities is not well known.
Methods: 92 consecutive patients with ST-elevation AMI treated with PCI and GP IIb/IIIa
inhibitors underwent 2-D echocardiograms, with and without echo contrast agent, within 24–72
hours.
Results: Only 4/92 (4.3%) had an LV thrombus, representing a significantly lower incidence than
that reported in the pre-PCI era. Use of contrast agents did not improve detection of LV thrombi
in our study.
Conclusion: The incidence of LV thrombus formation after acute MI, in the current era of rapid
reperfusion, is lower than what has been historically reported.
Background
A well-recognized complication of acute myocardial inf-
arction (AMI) is the development of a left ventricular (LV)
thrombus. Causes of LV thrombus include segmental dys-
function of the infarcted myocardium causing stasis,
endocardial tissue inflammation providing a thrombo-
genic surface, and a hypercoagulable state [1-6]. There is
evidence that LV thrombi usually develop within a few
days after AMI [2,7-9].
Historically, the incidence of LV thrombi complicating
AMI had been reported to be 20–40%, and may reach
60% among patients with large anterior wall AMI [10].
Early thrombolytic therapy reduces this incidence
[5,6,11]. However, there is little data on the incidence of
LV thrombus formation after primary percutaneous coro-
nary intervention (PCI), with concurrent use of IIb/IIIa
inhibitors, for AMI. We hypothesized that with improved
reperfusion using catheter-based techniques, together
with the use of potent platelet glycoprotein IIb/IIIa inhib-
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formation would be lower than what had been reported
in the pre-PCI era. To increase the sensitivity of standard
two-dimensional echocardiography (2-D echo) for detec-
tion of an LV thrombus, we used a third-generation con-
trast agent to outline the LV cavity structures.
Methods
Ninety-two consecutive patients presenting to our institu-
tion with ST elevation AMI and treated with PCI, rescue
angioplasty after failed thrombolysis, or 'facilitated' PCI
were enrolled in the study. Written informed consent was
obtained from the patients prior to enrolment. Baseline
demographic characteristics, pre- and post-intervention
Thrombolysis in Myocardial Infarction flow grade, type of
intervention, and other therapies instituted were
recorded. Two-dimensional echocardiography was per-
formed using a Vivid-7 ultrasound machine (GE Medical
Systems) within three days of the PCI, by a registered
sonographer, with and without an echo contrast agent
(Perflutren Lipid Microspheres – Definity®, Bristol-Myers
Squibb Inc), with digital storage for later off-line analysis.
Second harmonic imaging was used to optimise endocar-
dial visualization. Two level-3 echocardiographers
blinded to the clinical details separately reviewed the echo
images in each patient. The contrast images were stored
and reviewed separately from the non-contrast images. LV
thrombus was defined as an echodense mass with definite
margins, contiguous but distinct from the endocardium,
adjacent to an area of hypo- or akinetic myocardium [1].
In cases where there was a difference of interpretation
between the two readers, both readers reviewed the
images together and came to a consensus. A single reader,
blinded to the clinical and 2-D echo details of the patients
reviewed the angiographic data.
Results
Fifty-seven men and 35 women were studied, with a mean
age of 60 years (range: 30 – 87 years) (Table 1). Forty-one
patients had an inferior MI involving the right coronary
artery, 37 had an anterior MI with the left anterior
descending artery as the culprit vessel, 5 patients had an
infarct related to the left circumflex, 4 had an acute occlu-
sion of an obtuse marginal branch, 3 had occluded vein
grafts and one each had occlusion of the ramus interme-
dius branch and the major diagonal branch. All patients
had ST elevation on their presenting electrocardiograms.
Eight patients underwent PCI for failed thrombolysis and
10 had 'facilitated' PCI after administration of half-dose
thrombolytics. All but 5 patients received glycoprotein
IIb/IIIa inhibitor therapy. Stents were deployed in 78
patients, whereas 14 patients had angioplasty alone. Only
1 patient failed to achieve TIMI III flow in the infarct
related vessel.
Four patients, all with an anterior MI (4.3% of the total,
10.8 % of the anterior MI group), had a definite LV throm-
bus, both on unenhanced and enhanced imaging with
perflutren lipid microspheres (Table 2). The thrombus
was located in the LV apex in all 4 cases (Figure 1). All 4
were men (Table 3), with a mean age of 71 years (range 52
– 81 years); all demonstrated an occlusion of the proximal
or mid LAD, and achieved TIMI III flow after PCI. The
mean LV ejection fraction was 31% (range 20–40%).
None of the 4 had a prior history of coronary artery dis-
ease. Three of these patients had undergone primary PCI
and received IIb/IIIa therapy, whereas one patient, who
did not receive GP IIb/IIIa inhibitor therapy, underwent
rescue PCI after failing thrombolytic therapy. Echo con-
trast agent did not reveal LV thrombus in any patient
where one was not seen on routine, unenhanced 2-D
echocardiogram.
Discussion
Previous studies have shown that mural thrombi occur in
approximately 20% of all patients who do not receive
reperfusion therapy [10]. This incidence rises to 40% in
case of anterior AMI and further to 60% in cases of large
anterior AMI involving the LV apex10. Patients with LV
thrombi have a worse overall prognosis [13], with about
10% thrombi resulting in systemic embolization [10].
Strategies to prevent this complication therefore represent
an important therapeutic goal.
Although the introduction of thrombolytic therapy for
treatment of AMI improved survival, its impact on the
incidence of LV thrombus formation has varied. Bhatna-
gar, et-al showed a 3-fold reduction in the incidence of LV
Table 1: Baseline demographics
n(%) (Total n = 92)
Mean Age in Years (Range) 59 (30–87)
Males 57 (62%)
History of coronary disease 17 (18%)
Hypertension 47 (51%)
Congestive Heart Failure 2 (2%)
Diabetes Mellitus 22 (24%)
Medications on admission
- Beta-Blocker 19 (21%)
- ACEI 9 (10%)
- Aspirin 22 (24%)
- Clopidogrel 0
- Warfarin 1 (1%)
- Statins 14 (15%)
n: Number
% denotes percentage of each characteristic among total patients
ACEI: Angiotensin Converting Enzyme InhibitorPage 2 of 5
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binant tissue plasminogen activator [5]. A sub study of the
Gruppo Italiano per lo Studio della Sopravvivenza
nell'infarto miocardico (GISSI-2), however, failed to show
a significant reduction in the incidence of LV thrombus
formation in AMI patients with thrombolytic agents [14].
An analysis of the subsequent GISSI-3 database by Chi-
arella et al, however, showed a significant reduction in the
incidence of LV thrombus in patients with AMI [15]. In a
meta-analysis of 6 studies, Vaitkus and Barnathan found
an association between thrombolytic therapy and reduced
LV thrombus formation, although it did not achieve sta-
tistical significance [11].
Catheter-based reperfusion therapy is superior to throm-
bolytics in promoting early myocardial recovery, with
improved clinical outcomes [12]. Primary PCI, with or
without stenting, has thus become the treatment of choice
for patients with AMI in institutions with facilities for
emergency cardiac catheterization [16,17]. The introduc-
tion of potent glycoprotein IIb/IIIa (GP IIb/IIIa) inhibitor
agents has further improved the procedural outcomes for
PCI with stenting in AMI [12,18,19]. In one small study,
the incidence of LV thrombus formation after AMI in
patients undergoing primary PCI, was reported to be as
low as to 4% [20]. Porter et al, in a retrospective study of
AMI patients who received either thrombolytics or pri-
mary PCI, with or without GP IIb/IIIa inhibitors, reported
a 23.5% incidence of LV thrombus after anterior AMI [21].
Our study is unique in that it prospectively evaluates LV
thrombus formation in AMI patients receiving both pri-
mary PCI and GP IIb/IIIa inhibitors. It confirms a signifi-
cant reduction in this complication that parallels
improvement in other post-MI outcomes as a result of bet-
ter contemporary therapy. We also used echo contrast
agent in all patients and found no additive value in detec-
tion of post MI LV thrombi.
It is important to review the role of echocardiography in
the diagnosis of LV thrombi. The sensitivity and specificity
of 2-D echo in the diagnosis of LV thrombi has been
established, even with first and second-generation echo
equipment, to be in excess of 92% and 86–88%,
respectiviely1. With modern, improved imaging equip-
ment, the sensitivity is expected to be even higher. None-
theless 2-D echo has certain limitations. First, a small
thrombus (e.g., < 5–6 mm) may not be accurately
detected [22]. Second, differences in acoustic impedance
between endocardium and freshly formed thrombus may
not be sufficient to allow clear definition of the thrombus.
Third, various other anatomic structures, such as false ten-
dons or trabeculae, may confound the diagnosis [1].
The use of contrast agents has been reported to add to the
sensitivity of non-contrast 2-D echo [23] in the diagnosis
of LV thrombi, although in our study, contrast agents did
not detect any additional thrombi. The use of contrast
adds US $110 to the cost of each study and involves
approximately 5 minutes of additional imaging time. Per-
haps it would be reasonable to reserve contrast agents for
patients with sub-optimal 2D imaging which precludes
adequate visualization of the endocardium. Given the
small number of patients with thrombi in our study the
additive value of contrast should be interpreted with cau-
tion.
Conclusion
In conclusion, the incidence of early LV thrombus forma-
tion is lower (4% for all MI's, 11% for anterior MI's) in
this era of primary PCI, coupled with the use of potent
antithrombotic and anti-platelet agents, compared to his-
torical data in the pre-PCI era (up to 20 % for all MI's,
Thrombus in left ventricular apexFigure 1
Thrombus in left ventricular apex. Thrombus noted in 
left ventricular apex (white area in non-contrast enhanced 
image on left, black lucent area in contrast enhanced image 
on right)
Table 2: Relationship between infarct location and thrombus 
formation
Infarct Location Number of 
Patients
LV Thrombus n (%)




Total 92 4 (4.3)
n: Number
LV = Left ventricular
% represents percentage of a characteristic within each categoryPage 3 of 5
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agents did not improve detection of LV thrombi in our
study.
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